Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study
Open Access
Abstract
Introduction: Patients with chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) are at risk of developing gastric adenocarcinoma. Their diagnosis and management currently rely on histopathological guidance after random endoscopic biopsy sampling (Sydney biopsy strategy). This approach has significant flaws such as under-diagnosis, poor reproducibility and poor correlation between endoscopy and histology. This prospective, international multicentre study aims to establish whether endoscopy-led risk stratification accurately and reproducibly predicts CAG and IM extent and disease stage. Methods and analysis: Patients with CAG and/or IM on standard white light endoscopy (WLE) will be prospectively identified and invited to undergo a second endoscopy performed by an expert endoscopist using enhanced endoscopic imaging techniques with virtual chromoendoscopy. Extent of CAG/IM will be endoscopically staged with enhanced imaging and compared with standard WLE. Histopathological risk stratification through targeted biopsies will be compared with endoscopic disease staging and to random biopsy staging on WLE as a reference. At least 234 patients are required to show a 10 % difference in sensitivity and accuracy between enhanced imaging endoscopy-led staging and the current biopsy-led staging protocol of gastric atrophy with a power (beta) of 80 % and a 0.05 probability of a type I error (alpha). Ethics and dissemination: The study was approved by the respective Institutional Review Boards (Netherlands: MEC-2018-078; UK: 19/LO/0089). The findings will be published in peer-reviewed journals and presented at scientific meetings. Trial registration number: NTR7661; Pre-results.Keywords
Funding Information
- Maag Lever Darm Stichting (D17-22)
This publication has 25 references indexed in Scilit:
- British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinomaGut, 2019
- Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regionsGut, 2018
- Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Interobserver and intraobserver agreement for gastric mucosa atrophyBMC Gastroenterology, 2015
- The 5-Year Relative Survival Rate of Stomach Cancer in the USA, Europe and JapanJapanese Journal of Clinical Oncology, 2013
- Missed diagnosis of early gastric cancer or high-grade intraepithelial neoplasiaWorld Journal of Gastroenterology, 2013
- Screening for Gastric Premalignant Lesions with Narrow Band Imaging, White Light and Updated Sydney Protocol or Both?Digestive Diseases and Sciences, 2012
- Age-Specific Trends in Incidence of Noncardia Gastric Cancer in US AdultsJAMA, 2010
- Role of symptoms in diagnosis and outcome of gastric cancerWorld Journal of Gastroenterology, 2008
- A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopyEndoscopy, 2006